Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 11/20 | 0.45 |
| ▸ | ABL1 | P00519 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | JAK1 | P23458 | 1/20 | 0.40 |
| ▸ | GRM5 | P41594 | 1/20 | 0.38 |
| ▸ | VNN1 | O95497 | 1/20 | 0.38 |
| ▸ | MOK | Q9UQ07 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4318062 | 1.00 | F10 (0.45) | F10ABL1MAPK1SMN1; SMN2JAK1 | |
| SCHEMBL13664971 | 0.94 | F10 (0.42) | F10SMN1; SMN2GRM5 | |
| SCHEMBL13665085 | 0.92 | ABL1 (0.46) | F10ABL1SMN1; SMN2JAK1VNN1 | |
| SCHEMBL13664977 | 0.90 | ABL1 (0.43) | F10ABL1MAPK1SMN1; SMN2JAK1 | |
| SCHEMBL4319944 | 0.89 | F10 (0.44) | F10ABL1MAPK1SMN1; SMN2 | |
| SCHEMBL13664982 | 0.88 | JAK1 (0.41) | F10MAPK1SMN1; SMN2JAK1 | |
| SCHEMBL4325368 | 0.88 | SMN1; SMN2 (0.46) | F10SMN1; SMN2 | |
| SCHEMBL4331028 | 0.88 | SMN1; SMN2 (0.46) | F10MAPK1SMN1; SMN2 | |
| SCHEMBL4331029 | 0.88 | SMN1; SMN2 (0.46) | F10MAPK1SMN1; SMN2 | |
| SCHEMBL4316221 | 0.86 | SMN1; SMN2 (0.44) | F10MAPK1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060247273-A1 | Carbamoyl-type benzofuran derivatives | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2006-11-02 | — | — | US | claimed |
| EP-1666478-A1 | CARBAMOYL-TYPE BENZOFURAN DERIVATIVES | TANABE SEIYAKU CO., LTD. (JP) | 2006-06-07 | — | — | EP | claimed |
| US-7605158-B2 | Carbamoyl-type benzofuran derivatives | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-10-20 | — | — | US | disclosed |
| US-20060247273-A1 | Carbamoyl-type benzofuran derivatives | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2006-11-02 | — | — | US | disclosed |
| EP-1666478-A1 | CARBAMOYL-TYPE BENZOFURAN DERIVATIVES | TANABE SEIYAKU CO., LTD. (JP) | 2006-06-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060247273-A1 | Carbamoyl-type benzofuran derivatives | F12, F2, F3 | F10 8/4885ABL1 390/4885MAPK1 2230/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.